Profil
Carlo Casulo worked as a Director of Technical Operations at Alaunos Therapeutics, Inc. in 2006.
He was an Analyst at Paramount BioCapital, Inc. in 2005 and at Ascend Capital LLC from 2008 to 2013.
He also worked as a Research Associate at Leerink Partners LLC from 2006 to 2008.
Dr. Casulo received his undergraduate degree from City University of New York in 2000.
He earned his doctorate degree from Harvard Medical School in 2006 and his MBA from Harvard Business School in 2005.
Ehemalige bekannte Positionen von Carlo Casulo
| Unternehmen | Position | Ende |
|---|---|---|
Leerink Partners LLC
Leerink Partners LLC Investment Banks/BrokersFinance Provides brokerage services | Analyst-Equity | 28.02.2008 |
| ALAUNOS THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 31.05.2006 |
Paramount BioCapital, Inc.
Paramount BioCapital, Inc. Investment ManagersFinance Alternative investment manager | Corporate Officer/Principal | 31.03.2005 |
Ascend Capital LLC
Ascend Capital LLC Investment ManagersFinance Ascend Capital employs an opportunistic US-focused long/short equity investment strategy. They seek to generate superior risk-adjusted returns that maximize gains and minimize volatility over a broad range of market environments. They employ a variation of the Jones Model investing strategy with the intention of achieving capital appreciation in a broad range of market environments. The net market exposure of each account may vary significantly depending on the firm's assessment of shifting economic and market conditions, as well as particular long and short investing opportunities. Ascend Capital's strategy has neither a long nor short bias. Although their strategy focuses on equity and equity-related securities that are publicly traded, they may pursue a highly diverse range of investments and trading strategies. Ascend Capital may cause the accounts to invest a significant portion of their assets in one or more of the following: illiquid securities, including privately placed equity (of public and private companies), defaulted debt, bank debt and trade claims, bonds (convertible and non-convertible), other fixed-income investments and senior and subordinated tranches of asset-backed pools. Ascend Capital's strategy includes short selling. They expect the funds to utilize leverage on a moderate to extensive basis. The separate accounts utilize leverage in accordance with the investment guidelines for each account. The firm may cause the accounts to buy or sell (write) options, publicly traded and over-the-counter, covered and uncovered, on securities and securities indices, as well as options and forward contracts on currencies. They may also cause the accounts to engage in a variety of investment techniques involving arbitrage. addition, they may cause the accounts to engage in futures and other derivative transactions, typically for hedging of existing long and short positions. | Analyst-Equity | 10.09.2013 |
Ausbildung von Carlo Casulo
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
Ascend Capital LLC
Ascend Capital LLC Investment ManagersFinance Ascend Capital employs an opportunistic US-focused long/short equity investment strategy. They seek to generate superior risk-adjusted returns that maximize gains and minimize volatility over a broad range of market environments. They employ a variation of the Jones Model investing strategy with the intention of achieving capital appreciation in a broad range of market environments. The net market exposure of each account may vary significantly depending on the firm's assessment of shifting economic and market conditions, as well as particular long and short investing opportunities. Ascend Capital's strategy has neither a long nor short bias. Although their strategy focuses on equity and equity-related securities that are publicly traded, they may pursue a highly diverse range of investments and trading strategies. Ascend Capital may cause the accounts to invest a significant portion of their assets in one or more of the following: illiquid securities, including privately placed equity (of public and private companies), defaulted debt, bank debt and trade claims, bonds (convertible and non-convertible), other fixed-income investments and senior and subordinated tranches of asset-backed pools. Ascend Capital's strategy includes short selling. They expect the funds to utilize leverage on a moderate to extensive basis. The separate accounts utilize leverage in accordance with the investment guidelines for each account. The firm may cause the accounts to buy or sell (write) options, publicly traded and over-the-counter, covered and uncovered, on securities and securities indices, as well as options and forward contracts on currencies. They may also cause the accounts to engage in a variety of investment techniques involving arbitrage. addition, they may cause the accounts to engage in futures and other derivative transactions, typically for hedging of existing long and short positions. | Finance |
Paramount BioCapital, Inc.
Paramount BioCapital, Inc. Investment ManagersFinance Alternative investment manager | Finance |
Leerink Partners LLC
Leerink Partners LLC Investment Banks/BrokersFinance Provides brokerage services | Finance |
City University of New York
City University of New York Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc. BiotechnologyHealth Technology Develops a portfolio of immuno-oncology therapies | Health Technology |
Harvard Medical School
Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard Business School
Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
















